Tony Morales
Overview
Explore the profile of Tony Morales including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
933
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haling J, Sudhamsu J, Yen I, Sideris S, Sandoval W, Phung W, et al.
Cancer Cell
. 2014 Aug;
26(3):402-413.
PMID: 25155755
Numerous oncogenic mutations occur within the BRAF kinase domain (BRAF(KD)). Here we show that stable BRAF-MEK1 complexes are enriched in BRAF(WT) and KRAS mutant (MT) cells but not in BRAF(MT)...
2.
Newhouse B, Hansen J, Grina J, Welch M, Topalov G, Littman N, et al.
Bioorg Med Chem Lett
. 2011 May;
21(11):3488-92.
PMID: 21536432
The synthesis and biological evaluation of non-oxime pyrazole based B-Raf inhibitors is reported. Several oxime replacements have been prepared and have shown excellent enzyme activity. Further optimization of fused pyrazole...
3.
Ren L, Wenglowsky S, Miknis G, Rast B, Buckmelter A, Ely R, et al.
Bioorg Med Chem Lett
. 2011 Jan;
21(4):1243-7.
PMID: 21251822
The development of inhibitors of B-Raf(V600E) serine-threonine kinase is described. Various head-groups were examined to optimize inhibitor activity and ADME properties. Several of the head-groups explored, including naphthol, phenol and...
4.
Buckmelter A, Ren L, Laird E, Rast B, Miknis G, Wenglowsky S, et al.
Bioorg Med Chem Lett
. 2011 Jan;
21(4):1248-52.
PMID: 21211972
Virtual and high-throughput screening identified imidazo[1,2-a]pyrazines as inhibitors of B-Raf. We describe the rationale, SAR, and evolution of the initial hits to a series of furo[2,3-c]pyridine indanone oximes as highly...
5.
Hatzivassiliou G, Song K, Yen I, Brandhuber B, Anderson D, Alvarado R, et al.
Nature
. 2010 Feb;
464(7287):431-5.
PMID: 20130576
Activating mutations in KRAS and BRAF are found in more than 30% of all human tumours and 40% of melanoma, respectively, thus targeting this pathway could have broad therapeutic effects....
6.
Hansen J, Grina J, Newhouse B, Welch M, Topalov G, Littman N, et al.
Bioorg Med Chem Lett
. 2008 Aug;
18(16):4692-5.
PMID: 18676143
Herein we describe a novel pyrazole-based class of ATP competitive B-Raf inhibitors. These inhibitors exhibit both excellent cellular potency and striking B-Raf selectivity. A subset of these inhibitors has demonstrated...
7.
Baldwin S, Powell T, Wonderling R, Keiser K, Morales T, Hunter S, et al.
Am J Vet Res
. 2003 Dec;
64(12):1465-71.
PMID: 14672421
Objective: To use transient and stable transfection of Chinese hamster ovary cells to clone the gene encoding feline erythropoietin (feEPO) protein, characterize the expressed protein, and assess its biological activity....
8.
Tang L, Morales T, Boroughs K, Cailles Lo-Keiser K, Sellins K, Stedman K, et al.
Mol Immunol
. 2003 Jan;
39(12):719-27.
PMID: 12531283
Our previous study showed that recombinant canine IL-13 (rcaIL-13) stimulated production of allergen-specific IgE in vitro by peripheral blood mononuclear cells (PBMC) from flea allergen-sensitized dogs. This has also been...
9.
Wonderling R, Powell T, Baldwin S, Morales T, Snyder S, Keiser K, et al.
Vet Immunol Immunopathol
. 2002 Sep;
89(1-2):13-27.
PMID: 12208047
Type I interferons (IFN) are important mediators of the host defense against viral infections in mammals. In humans multiple subtypes of IFN-alpha exist, most of which possess antiviral activity. Little...